Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance
- PMID: 33142805
- PMCID: PMC7663405
- DOI: 10.3390/ijms21218159
Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance
Abstract
Immune checkpoint molecules are the antigen-independent generator of secondary signals that aid in maintaining the homeostasis of the immune system. The programmed death ligand-1 (PD-L1)/PD-1 axis is one among the most extensively studied immune-inhibitory checkpoint molecules, which delivers a negative signal for T cell activation by binding to the PD-1 receptor. The general attributes of PD-L1's immune-suppressive qualities and novel mechanisms on the barrier functions of vascular endothelium to regulate blood vessel-related inflammatory diseases are concisely reviewed. Though targeting the PD-1/PD-L1 axis has received immense recognition-the Nobel Prize in clinical oncology was awarded in the year 2018 for this discovery-the use of therapeutic modulating strategies for the PD-L1/PD-1 pathway in chronic inflammatory blood vessel diseases is still limited to experimental models. However, studies using clinical specimens that support the role of PD-1 and PD-L1 in patients with underlying atherosclerosis are also detailed. Of note, delicate balances in the expression levels of PD-L1 that are needed to preserve T cell immunity and to curtail acute as well as chronic infections in underlying blood vessel diseases are discussed. A significant link exists between altered lipid and glucose metabolism in different cells and the expression of PD-1/PD-L1 molecules, and its possible implications on vascular inflammation are justified. This review summarizes the most recent insights concerning the role of the PD-L1/PD-1 axis in vascular inflammation and, in addition, provides an overview exploring the novel therapeutic approaches and challenges of manipulating these immune checkpoint proteins, PD-1 and PD-L1, for suppressing blood vessel inflammation.
Keywords: PD-L1; PD-L2; atherosclerosis and blood vessel inflammatory diseases; coronary artery disease; programmed death-1 (PD-1).
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
Similar articles
-
PD1/PD-L1 Axis in Uro-oncology.Curr Drug Targets. 2020;21(13):1293-1300. doi: 10.2174/1389450121666200326123700. Curr Drug Targets. 2020. PMID: 32213156 Review.
-
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.Cancer Med. 2020 Nov;9(21):8086-8121. doi: 10.1002/cam4.3410. Epub 2020 Sep 2. Cancer Med. 2020. PMID: 32875727 Free PMC article. Review.
-
The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.J Leukoc Biol. 2018 Mar;103(3):565-575. doi: 10.1189/jlb.3MA0717-283. Epub 2017 Dec 29. J Leukoc Biol. 2018. PMID: 28848042 Free PMC article. Review.
-
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway.Life Sci. 2021 Oct 1;282:119813. doi: 10.1016/j.lfs.2021.119813. Epub 2021 Jul 10. Life Sci. 2021. PMID: 34256042 Review.
-
The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.Eur J Pharmacol. 2021 Mar 15;895:173867. doi: 10.1016/j.ejphar.2021.173867. Epub 2021 Jan 15. Eur J Pharmacol. 2021. PMID: 33460617 Review.
Cited by
-
Keeping the Failing Heart in Check: Can Modulating Immune Checkpoints Promote Myocardial Recovery?JACC Basic Transl Sci. 2022 Nov 14;7(11):1140-1142. doi: 10.1016/j.jacbts.2022.07.009. eCollection 2022 Nov. JACC Basic Transl Sci. 2022. PMID: 36687277 Free PMC article.
-
An integrative review of nonobvious puzzles of cellular and molecular cardiooncology.Cell Mol Biol Lett. 2023 May 23;28(1):44. doi: 10.1186/s11658-023-00451-y. Cell Mol Biol Lett. 2023. PMID: 37221467 Free PMC article. Review.
-
Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.Comput Struct Biotechnol J. 2022 Sep 15;20:5150-5161. doi: 10.1016/j.csbj.2022.09.017. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 36187919 Free PMC article. Review.
-
Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer.J Transl Med. 2024 Jul 20;22(1):672. doi: 10.1186/s12967-024-05472-5. J Transl Med. 2024. PMID: 39033271 Free PMC article.
-
Costimulation blockade and Tregs in solid organ transplantation.Front Immunol. 2022 Sep 2;13:969633. doi: 10.3389/fimmu.2022.969633. eCollection 2022. Front Immunol. 2022. PMID: 36119115 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials